JP Morgan Maintains Underweight on Integra Lifesciences, Raises Price Target to $13

Benzinga · 10/31 18:40
JP Morgan analyst Robbie Marcus maintains Integra Lifesciences (NASDAQ:IART) with a Underweight and raises the price target from $12 to $13.